We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

WBC Count Could Predict Severity of COVID-19 Symptoms

By LabMedica International staff writers
Posted on 03 Feb 2025
Image: Leukocyte count represents an easily accessible, inexpensive clinical marker (Photo courtesy of 123RF)
Image: Leukocyte count represents an easily accessible, inexpensive clinical marker (Photo courtesy of 123RF)

The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment and fatigue are among the most common lingering effects, with a staggering 70% of patients suffering from cognitive impairment. Older adults, particularly women, are disproportionately affected. Despite significant advances in understanding COVID-19 since its emergence in 2020, several aspects of its impact on the human body remain unclear. While COVID-19 is primarily a respiratory disease, research has revealed widespread effects on multiple organ systems. Previous studies have identified an exaggerated immune response to COVID-19 infection. Now, a new study has shed light on a potential indicator of the most likely patients to experience severe symptoms of COVID-19 infection: leukocyte (white blood cell) count.

This study drew on data from the Women's Health Initiative, a comprehensive research project funded by the National Institutes of Health (NIH, Bethesda, MD, USA). Researchers sought to investigate pre-existing risk factors that might make older adults, particularly postmenopausal women, more susceptible to prolonged and severe symptoms. They examined the relationship between leukocyte count, a readily available clinical marker of systemic inflammation, and COVID disease outcomes. Their findings, published in the journal Menopause, suggest that leukocyte count is a reliable predictor of COVID symptom severity in postmenopausal women. This research contributes to the growing evidence that low-grade inflammation is not only an outcome of severe COVID-19 symptoms but also a potential precursor to the acute infection. Further investigation is needed, but the initial findings hold promise, as leukocyte count represents a relatively inexpensive and easily accessible clinical marker.

“As the authors highlight, post-acute sequelae of severe acute respiratory coronavirus 2 infection significantly affects quality of life, often leading to severe disability,” said Dr. Monica Christmas, associate medical director for The Menopause Society. “This effect is particularly pronounced in women, who already experience higher rates of cognitive impairment after menopause. By understanding underlying factors, we can better address these challenges and work to mitigate the cascade of symptoms that follow.”

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Hybrid Pipette
SWITCH

Channels

Molecular Diagnostics

view channel
Image: The liquid biopsy approach measures randomness in DNA methylation patterns to detect early-stage cancer signals in blood (Photo courtesy of 123RF)

Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability

Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more